Status:
SUSPENDED
Bismuth Quadruple Therapy With Cefuroxime for Helicobacter Pylori Eradication Treatment
Lead Sponsor:
Shanghai East Hospital
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
To observe the efficacy of cefuroxime-containing bismuth quadruple regimen in the eradication treatment of Helicobacter pylori, and to evaluate whether it can be used as a remedial treatment for Helic...
Detailed Description
Introducing cefuroxime into the remedy treatment of Helicobacter pylori, on the one hand, the investigators will observe whether cefuroxime can replace tetracycline like amoxicillin, on the other hand...
Eligibility Criteria
Inclusion
- Employees, family members, and patients with positive C13 breath test in our hospital;
- Has received one or more previous Helicobacter pylori eradication therapy (no use of cefuroxime or tetracycline), and the result is still positive by C13 breath test;
- Willing to undergo gastroscopy and HP cultivation and identification;
- Age 18-70, gender unlimited;
- Willing to participate in and cooperate with the study, and willing to sign the informed consent.
Exclusion
- Drugs that may affect the study results, such as PPI, H2 blockers, bismuth agents, antibiotics, etc. were taken in the 4 weeks before enrollment;
- Patients with gastrointestinal malignancy tumor;
- Patients with gastrinoma;
- After gastric or esophageal surgery;
- Suffers from serious diseases of the heart, lung, kidney, liver, blood, nervous system, endocrine system or mental system;
- Patients with contraindications or previous allergic reactions to the drugs used in this study;
- Pregnant or breastfeeding women;
- Patients with other medical conditions that may increase the treatment side effects;
- Those who cannot give informed consent;
- Has participated in other drug trials within 3 months;
- Not considered suitable for participants by the investigator.
Key Trial Info
Start Date :
August 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT04723472
Start Date
August 1 2023
End Date
December 31 2025
Last Update
November 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai East Hospital
Shanghai, Shanghai Municipality, China, 200120